Latest news
Lumos Diagnostics Receives US$767,800 FebriDx® Purchase Order from PHASE Scientific - KalkineKalkine · Tue, 04 Aug 2026 03:54:05 GMTLumos Diagnostics (ASX:LDX) Secures US$767,800 FebriDx® Order from PHASE Scientific - KalkineKalkine · Tue, 04 Aug 2026 01:12:00 GMTCeretas (ASX:CTS) Brings Alzheimer’s Ultrasound Venture to the ASX After A$8m IPO—Can Clinical Progress Drive Long-Term Value? - KalkineKalkine · Tue, 28 Jul 2026 13:10:00 GMTLumos Diagnostics Reports 875% Surge in FebriDx Revenue Amid US Commercial Expansion and CLIA Waiver Milestone Payments - Kalkine MediaKalkine Media · Mon, 27 Jul 2026 07:00:00 GMTLumos Diagnostics Reports 875% FebriDx Revenue Growth Driven by US Commercialisation and CLIA Waiver Milestone Payments - KalkineKalkine · Mon, 27 Jul 2026 07:00:00 GMTOneview Healthcare (ASX:ONE) Falls 9% as Small-Cap Health-Tech Volatility Returns—Can Its Digital-Care Strategy Win Back Investors? - KalkineKalkine · Mon, 27 Jul 2026 04:43:00 GMT